Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Mingozzi

Showing results (91-100 of 138) with videos related to

Pageof 14
Sort By:
Science Translational Medicine|April 9, 2010
Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindnessDefne Amado, Federico Mingozzi, Daniel Hui, et al.
Molecular Therapy. Methods & Clinical Development|January 21, 2021
Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vectorGiulia De Sabbata, Florence Boisgerault, Corrado Guarnaccia, et al.
Scientific Reports|November 5, 2016
Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patientsElisa Masat, Pascal Laforêt, Marie De Antonio, et al.
Nature Medicine|March 21, 2007
CD8(+) T-cell responses to adeno-associated virus capsid in humansFederico Mingozzi, Marcela V Maus, Daniel J Hui, et al.
Hepatology (Baltimore, Md.)|March 21, 2017
Autophagy determines efficiency of liver-directed gene therapy with adeno-associated viral vectorsMarianna Hösel, Anke Huber, Susanne Bohlen, et al.
The Journal of Clinical Investigation|July 19, 2013
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapyVirginia Haurigot, Sara Marcó, Albert Ribera, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 29, 2010
Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogsVirginia Haurigot, Federico Mingozzi, George Buchlis, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 17, 2013
Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopesDaniel J Hui, Etiena Basner-Tschakarjan, Yifeng Chen, et al.
Ebiomedicine|October 11, 2020
Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defectsPasqualina Colella, Pauline Sellier, Manuel J Gomez, et al.
Human Gene Therapy|September 11, 2019
Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar SyndromeSem J Aronson, Philippe Veron, Fanny Collaud, et al.
Pageof 14

Showing results (91-100 of 138) with videos related to

Sort By:
Pageof 14
Science Translational Medicine|April 9, 2010
Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindnessDefne Amado, Federico Mingozzi, Daniel Hui, et al.
Molecular Therapy. Methods & Clinical Development|January 21, 2021
Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vectorGiulia De Sabbata, Florence Boisgerault, Corrado Guarnaccia, et al.
Scientific Reports|November 5, 2016
Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patientsElisa Masat, Pascal Laforêt, Marie De Antonio, et al.
Nature Medicine|March 21, 2007
CD8(+) T-cell responses to adeno-associated virus capsid in humansFederico Mingozzi, Marcela V Maus, Daniel J Hui, et al.
Hepatology (Baltimore, Md.)|March 21, 2017
Autophagy determines efficiency of liver-directed gene therapy with adeno-associated viral vectorsMarianna Hösel, Anke Huber, Susanne Bohlen, et al.
The Journal of Clinical Investigation|July 19, 2013
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapyVirginia Haurigot, Sara Marcó, Albert Ribera, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 29, 2010
Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogsVirginia Haurigot, Federico Mingozzi, George Buchlis, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 17, 2013
Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopesDaniel J Hui, Etiena Basner-Tschakarjan, Yifeng Chen, et al.
Ebiomedicine|October 11, 2020
Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defectsPasqualina Colella, Pauline Sellier, Manuel J Gomez, et al.
Human Gene Therapy|September 11, 2019
Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar SyndromeSem J Aronson, Philippe Veron, Fanny Collaud, et al.
Pageof 14